Match Document Document Title
US20130274246 Therapeutic Treatment for Metabolic Syndrome, Type 2 Diabetes, Obesity, or Prediabetes  
The present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of increasing the ratio of...
US20120039913 Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders  
The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.
US20150079159 Formulations and Methods for Delaying Onset of Chronic Neuropathic Pain  
A dosing regimen for formulations that contain a therapeutic dosage of a site 1 sodium channel blocker, where the dosing regimen provides a prolonged nerve block and is in an effective amount to...
US20150065528 PARALYTIC SHELLFISH POISON  
The invention concerns a paralytic shellfish poison for the treatment of itching in a human being or another mammal.
US20130203777 Identification of Stabilizers of Multimeric Proteins  
Disclosed herein are compounds and compositions thereof which find use in increasing stability of TTR tetramers reducing its tendency to misfold and form aggregates. Also provided herein are...
US20150157607 Compounds that Enhance Atoh1 Expression  
This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a...
US20110046126 Use of 2,4-Pyrimidinediamines For the Treatment of Atherosclerosis  
Novel methods and compositions for the prevention and treatment of all forms of atherosclerosis with 2,4-pyrimidinediamine compounds are described. Also disclosed is the coating of prosthetic...
US20140308296 PAR-1 Antagonists for Use in the Treatment or Prevention of Influenza Virus Type A Infections  
The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR1 antagonists for treating or preventing influenza virus type A infections, in...
US20120213802 PAR-1 Antagonists for Use in the Treatment or Prevention of Influenza Virus Type A Infections  
The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR1 antagonists for treating or preventing influenza virus type A infections, in...
US20120316136 TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS  
The present patent application relates to treatment of a respiratory disorder using TRPA1 antagonists. Particularly, the present patent application relates to treatment of a respiratory disorder...
US20110014204 Cancer Chemoprevention Strategy Based on Loss of Imprinting of IGF2  
The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFR1, are disclosed...
US20090082373 Uses of 2-[piperidinyl]methyl-2, 3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one for providing an analgesic effect, anti-allergic effect and histamine H1 receptor antagonism effect  
The present invention discloses new uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5( 6H)-one in providing an analgesic effect in a patient, treating passive cutaneous...
US20140128390 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR  
Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions...
US20140051685 THERAPEUTIC TREATMENT FOR METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR PREDIABETES  
The present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, and the metabolic...
US20100311683 CYTIDINE ANALOGS FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES  
The present invention provides methods of treating a patient having a higher risk myelodysplastic syndrome, which comprises administering to a patient having a higher risk myelodysplastic syndrome...
US20130217685 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR  
The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with...
US20130039976 Sodium channel blocker for treatment of loss of superficial sensitivity  
The invention concerns a sodium channel blocker for the treatment of a reduction or loss of superficial sensitivity or sense of touch of a human being or another mammal.
US20150164903 METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY  
A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent...
US20120141491 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERS AND PATHOGENIC INFECTIONS  
The subject application provides small compounds that are able to increase/enhance autophagy in various cells. These compounds are useful in augmenting existing treatments of various cancers,...
US20150126449 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use  
The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations...
US20140343051 METHODS TO MODULATE ACUTE MYELOID LEUKEMIA STEM/PROGENITOR CELL EXPANSION AND/OR DIFFERENTIATION  
Novel methods for modulating acute myeloid leukemia stem/progenitor cell expansion and/or differentiation are disclosed. These methods are based on the use of aryl hydrocarbon receptor (AhR)...
US20140324016 Methods and Devices for Renal Nerve Blocking  
A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from...
US20150202206 SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY  
Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a...
US20140248264 SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY  
Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a...
US20120276088 SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY  
Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a...
US20120040966 ANTI-VIRAL COMPOUNDS, TREATMENT, AND ASSAY  
The compounds provided herein are suitable for inhibiting a virus in a patient and for treating a patient suffering from a viral infection such as an influenza virus. Also provided is a method for...
US20130129677 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections  
Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of...
US20150126496 DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDERS  
The invention relates to methods for diagnosis and treatment of autism spectrum disorders, particularly for autism spectrum disorders characterized by increased head size (circumference) and...
US20140329841 Neosaxitoxin Combination Formulations for Prolonged Local Anesthesia  
Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were...
US20140288103 Neosaxitoxin Combination Formulations for Prolonged Local Anesthesia  
Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were...
US20140080780 identification of compounds that disperse tdp-43 inclusions  
Herein, methods of modulating inclusion formation and stress granules in cells are described. The methods comprise contacting a cell with an inclusion inhibitor. Methods for screening for...
US20130143896 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY  
The present invention relates to substituted isoxazolo-quinazolines which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein...
US20110190324 METHODS OF TREATING ATHEROSCLEROSIS  
The present invention relates to adenosine A3 receptor antagonists and their use for the prevention and treatment of atherosclerosis by administering to a mammal, in need thereof, a...
US20140349992 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF  
Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as...
US20150105327 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VprBP-RELATED CANCERS  
This disclosure provides methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity. Also provided are methods of determining the...
US20110105494 HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS  
This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease. wherein X, R2, R3, and R4 are...
US20110105493 HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS  
This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease. wherein X, R2, R3, and R4 are...
US20110105492 ARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS  
This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease wherein X, R2, R3, and R4 are...
US20140179682 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF  
Compounds that modulate GluR5 activity and methods of using the same are disclosed.
US20110015201 HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE  
The present disclosure provides for compounds, pharmaceutical preparations, kits and methods for the inhibition of the Hh pathway and the alleviation of cancer and developmental disorders...
US20110064671 MODULATION OF BLOOD BRAIN BARRIER PERMEABILITY  
The present invention relates to a method of increasing blood brain barrier permeability in a subject. This method involves selecting a subject who would benefit from increased blood brain barrier...
US20130190335 FLUORESCENT ANTAGONISTS OF THE A3 ADENOSINE RECEPTOR  
Disclosed are compounds of the formula (I) which are fluorescently labeled antagonists of the A3 adenosine receptor: wherein A, R1, R2, and Y are as described herein. Also disclosed are diagnostic...
US20110312956 ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING  
This invention provides novel arylindenopyrimidines of the Formula (I), and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A1...
US20120122852 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE  
The invention concerns tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit of general formula (I): Wherein A, P, Y, R1, R2 and R3 are as defined herein. The invention...
US20110262442 COMPOSITIONS FOR TREATING CNS DISORDERS  
The present invention provides combination therapies for treating a disease, disorder, or condition, and methods thereof.
US20130281448 SMALL MOLECULE COMPOUNDS FOR TARGETING INFLAMMATORY CONDITIONS  
Provided herein are small molecule compounds for the treatment of inflammatory conditions, and pharmaceutical compositions and methods relating thereto. For example, provided herein are...
US20140051689 Polycyclic Agents for the Treatment of Respiratory Syncytial Virus Infections  
Compounds of formula (I), and their use as in the treatment of infections involving viruses of the Pneumovirinae sub-family (RSV) are disclosed. In the formula ring (A) may be phenyl, pyridyl...
US20110237611 CHEMICAL PERMEATION ENHANCERS ENHANCE NERVE BLOCKADE BY TOXINS  
Chemical permeation enhancers (CPEs) improve access of local anesthetics to the nerve, thereby improving their performance. Surfactants, representing three CPE sub-groups: anionic, cationic, and...
US20140038922 WNT PROTEIN SIGNALLING INHIBITORS  
The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment...
US20110136813 WNT PROTEIN SIGNALLING INHIBITORS  
The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment...